Dr. Andrew Huberman — Peptides, Performance, and Protocols

Why this is in the vault

Huberman is the canonical first-principles voice on performance neuroscience. This episode is one of his most applied — covering the full peptide landscape, revised training principles from working with Dorian Yates, psychedelic protocols, TMS neuroplasticity interventions, and a book overview. Direct intersection with Ray's tirzepatide context: Huberman explains retatrutide vs tirzepatide distinctions (triple agonist adds glucagon), flags micro-dosing for neuroprotection, and discusses muscle-sparing properties — all live health-decision territory.

Episode summary

Wide-ranging 2h conversation between Tim Ferriss and Andrew Huberman recorded in Malibu. Covers: (1) lessons from training with Dorian Yates on low-volume high-intensity programming, (2) revised psychedelics thinking including MDMA + psilocybin combination and a one-day TMS/DCS neuroplasticity protocol, (3) a thorough survey of the peptide landscape from GLPs to growth hormone secretagogues to BPC-157 to pinealon, (4) the organizing principle of cortisol bookending for daily health, (5) frontier sleep interventions, and (6) the structure of Huberman's forthcoming book "Protocols: An Operating Manual for the Human Body" (September 15 pub date). Huberman's consistent framing: identify the principle, then choose tools that fit your context — not protocol worship.

Key arguments / segments

• [00:00–00:05] Dean Potter documentary "The Dark Wizard" — energy channeled toward beauty vs competition; performance peaks when you stop competing and start chasing pure experience. Sets the philosophical frame for the episode.

• [00:05–00:27] Dorian Yates training collaboration — trains with Yates in LA and Marbella. Low-volume high-intensity vindicated by peer-reviewed data. Huberman's 6-day split: legs / rest / chest+back+neck / HIIT cardio / shoulders+arms / long slow movement. Each muscle group hit directly once, indirectly once. Key insight: published hypertrophy studies assume no cardio — real-world programming must account for the collision.

• [00:27–00:50] Psychedelics update — MDMA (125mg) for embodied feeling access; high-dose psilocybin (4–5g) for structure-of-thinking revelation. MDMA + psilocybin combination ("hippie flipping") eliminates the classic MDMA energy hangover. Both require clinical guide, golden 2–3 week plasticity window post-session is when behavioral work matters most. Caution: cannabis near these compounds significantly increases risk.

• [00:47–00:56] TMS / descloerene one-day protocol — Huberman co-founded Ampa Health with Dr. Jonathan Downer (University of Toronto). Oral descloerene (DCS) ~125mg taken one hour before TMS, compresses a 5-day 10x/day stimulation schedule into a single day. Huberman reports ~90% reduction in generalized anxiety disorder and OCD lasting 3–4 months per session. Some patients report 18 months durability for MDD.

• [00:56–01:00] Peptides — foundational framing. Abu Bakri's framework: pharma historically mined plants; now mining the body. GLPs are the proof-of-concept — GLP agonists at 100x raise treat diabetes; at 1000x drive robust weight loss. Risk: includes muscle loss without resistance training.

• [01:00–01:03] GLP landscape — retatrutide (Eli Lilly, pending release) hits GLP + GIP + glucagon, most effective weight loss peptide, spares more muscle than others. Gray market retatrutide already circulating. Micro-dosing trend (~1/10 prescribed dose) for neuroprotective and cognitive effects, distinct from metabolic pathway. Huberman notes glaucoma data: tirzepatide may reduce eye pressure.

• [01:01–01:03] Growth hormone secretagogues — sermorelin, ipamorelin, tesamorelin, CJC variants. 3–8x GH/IGF-1 increase. Huberman tried sermorelin: dramatically increased slow-wave sleep, nuked REM, spiked PSA (returned to normal on discontinuation). Verdict: if you want GH effects, pharma-grade somatotropin (1–2 IUs, 5 nights/week) is cleaner than secretagogues.

• [01:03–01:12] BPC-157 — body protection compound, peptide isolated from gastric juice. Impressive animal data (cartilage regrowth, fibroblast migration, angiogenesis, nerve regrowth). Zero published human trials. Huberman uses only acutely for injury; no ongoing use. Not mutagenic/carcinogenic but stimulates angiogenesis — theoretical concern for tumor vascularization. Source: compounding pharmacies (Tailor Made, Upstate, Revive) preferred over gray market. TB-500 + BPC = "Wolverine stack."

• [01:10–01:12] Gray market risks — Peptide Sciences shut down. Contamination (lipopolysaccharide), purity issues. Ferriss took Wolverine stack post-elbow surgery, has no idea if it helped. Huberman's framework: if you want clean results, pharma-grade GH beats stacked gray market peptides.

• [01:11–01:17] Pinealon — not from the pineal (made in neocortex). Subcutaneous injection or oral. Huberman reports dramatically elevated REM (3h personal best), no disruption to slow-wave, with multi-night carryover. Hypothesized mechanism: pineal regeneration (animal data). Occasional use only. One known contact uses it for daytime creative/cognitive state. Source: compounding pharmacy with prescription. Abood recommends daytime use for cognition.

• [01:11–01:12] Epithalon — from pineal gland, claimed histone/DNA preservation, some retinitis pigmentosa animal data. Huberman tried capsule form with morning sunlight for jet lag — possible clock shift acceleration but inconclusive. Not planning to repeat.

• [01:14–01:16] Alpha-GPC (900mg) — choline donor, can replace caffeine for late-day workouts without sleep disruption; actually increases REM sleep. Enables high-intensity late training while maintaining sleep quality.

• [01:17–01:27] Peptide sociology and marketplace — GLP revolution made injections culturally acceptable, opening the market. Primary actual users: women seeking skin/anti-aging effects (GHK copper + red light) and low-dose GLP-class peptides, not gym bros. Huberman backs one startup doing verified supply chain authentication. Market opportunity: pharma-grade peptide pens (dial-in dosing vs syringes).

• [01:40–01:45] AI for personalized health — Huberman bullish on LLMs as personal health analysts. Multiple anecdotes of people with top-tier doctors still finding actionable insights by uploading genome + wearables + labs to LLMs. Eddie Chang (UCSF): next horizon is AI trained on neural activity, not just internet text.

• [01:45–01:49] Writing to the nervous system — frontier sleep interventions: bed rocking to induce sleep (vestibular), MIT startup sleep mask that stimulates eye movements behind ear to induce sleep in <6 minutes. Prediction: sleep is where "writing to the nervous system" breaks through first, after wearables dominated "reading."

• [01:50–02:03] Huberman's book "Protocols" — 7 chapters: Sleep, Exercise, Stress, Light, Neuroplasticity, and Personal Development (grief science, Jim Hollis "shut up / suit up / show up" + heart's desires framework). Pub: September 15. Huberman Lab website has AI-linked timestamps for episodes.

Notable claims

1. Retatrutide muscle-sparing vs semaglutide — triple agonist (GLP/GIP/glucagon) spares more muscle than GLP-only agonists. Resistance training recommended regardless.
2. Micro-dose GLP for neuroprotection — 1/10 prescribed dose tirzepatide/retatrutide showing cognitive/neuroprotective signals independent of weight loss.
3. Sermorelin spikes PSA — Huberman's personal experience: PSA elevated on sermorelin, returned to baseline on discontinuation. No mechanistic explanation found.
4. MDMA + psilocybin eliminates MDMA hangover — consistent with facilitator lore; psilocybin session next day eliminates the "energetic crash" typical of MDMA alone.
5. Pinealon carryover REM enhancement — multi-night carryover from single administration; Huberman gets ~3h REM on pinealon nights.
6. One-day TMS/DCS protocol — 90% GAD/OCD reduction for 3–4 months from single-day protocol. Huberman is a co-founder of Ampa Health (disclosed).
7. Alpha-GPC (900mg) increases REM — enables late training without caffeine, boosts REM as side effect.
8. Cortisol bookending principle — high morning cortisol → low evening cortisol is the master principle; all individual protocols (sunlight, cold, caffeine, exercise) are just tools serving this.
9. Exhale-emphasized breathing increases nighttime HRV — even brief daytime deliberate exhales improve nocturnal HRV readout.
10. Tirzepatide may reduce eye pressure — early glaucoma data flagged.

Guests

Andrew Huberman, Ph.D. — Neuroscientist and tenured professor, Departments of Neurobiology and Ophthalmology, Stanford University School of Medicine. Runs the Huberman Lab. Author of "Protocols: An Operating Manual for the Human Body" (September 2026). Co-founder of Ampa Health (TMS/DCS neuroplasticity). Host of the Huberman Lab podcast. Long-standing collaborator with Tim Ferriss; prior episode April 2026.

Sponsorship

ProLon (science-backed Fasting Mimicking Diet; cellular renewal via fasting). Additional sponsors named in show notes not captured in transcript excerpt.

Mapping against Ray Data Co

Direct health intersections (high priority):

• Tirzepatide in use — Ray is on tirzepatide since 2026-06-11. Huberman distinguishes tirzepatide from retatrutide (retatrutide adds glucagon axis = more aggressive, Huberman explicitly says "careful with that one"). Confirms tirzepatide micro-dosing trend for neuroprotective effects at 1/10 dose. Ray should be aware this is a different risk profile than standard metabolic dosing.
• Muscle preservation concern — both Huberman and Ferriss note GLP-class drugs cause muscle loss; Huberman says retatrutide "spares some muscle." Ray should be tracking lean mass metrics alongside weight.
• Gout interaction — NOT discussed in this episode. The tirzepatide + uric acid relationship is documented separately in vault; this episode adds no new signal.
• PSA + GH secretagogues — Ray's age (36) and health context: if ever considering sermorelin/ipamorelin, Huberman's personal PSA spike is a notable caution flag even if mechanism unknown.

Training signal:

• Dorian Yates low-volume high-intensity framework validates a time-efficient approach. The "6 workouts, none long" structure is directly applicable for a founder schedule. Huberman's explicit point: published hypertrophy literature assumes no cardio — real-world split must account for collisions.

Sleep stack signal:

• Alpha-GPC (900mg) for late-day workouts + REM improvement is a clean, low-risk protocol worth tracking.
• Pinealon for occasional REM enhancement is novel; low data but Huberman's personal monitoring (blood work throughout) provides some reassurance.

AI-for-health thesis:

• Huberman's LLM-as-personal-health-analyst framing validates the RDCO health data + AI stack direction. Multiple high-net-worth anecdotes of LLMs surfacing insights missed by elite physicians.

RDCO business angle:

• Verified peptide supply chain as an open market need — Ferriss mentions backing one startup doing authentication. This is a potential data/AI wedge: clean sourcing verification + blood work correlation platform.

Related

• [[2026-04-19-tim-ferriss-huberman-foundations-physical-mental-performance]] — prior Huberman/Ferriss episode; foundations of sleep, light, stress, exercise
• [[2026-05-11-tim-ferriss-current-longevity-stack]] — Ferriss's own current supplement/peptide stack; cross-reference for what Tim is personally running
• [[2026-06-24-gout-management-protocol]] — Ray's active gout protocol; tirzepatide intersections
• [[research/2026-07-20-tirzepatide-allopurinol-gout-maintenance-monitoring]] — tirzepatide + allopurinol monitoring context for Ray's current protocol
• [[research/2026-06-18-tirzepatide-uric-acid-longitudinal-trajectory]] — longitudinal uric acid data under tirzepatide